Skip to main content

Cardiovascular

Featured Article
According to study findings, higher blood pressure variability modestly increases the risk of atrial fibrillation.
Mark Munger, PharmD, explains why pharmacists need to be vigilant on medication administration records for all patients, and intervene when necessary to avoid unnecessary drug misadventuring—…

Insights

Mark Munger, PharmD, explains why pharmacists need to be vigilant on medication administration records for all patients, and intervene when necessary to avoid unnecessary drug misadventuring—especially in heart failure.
Mark Munger, PharmD, discusses why the search for improving outcomes in HFrEF using newer anti-coagulants continues.
Mark Munger, PharmD, discusses recent study findings, which show that ranolazine increases the adverse effect profile of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, raising concern for patient safety.
Kiersten Combs, vice president of US Cardiovascular & Metabolic Disease, and Jim McDermott, vice president of US Medical Affairs and Metabolism, both at AstraZeneca, highlight how the use of Farxiga and other SGLT2 inhibitors impact payers and…

Interactive Features

Most patients who received guideline-recommended medication had doses lower than those recommended, the researchers note.
What percentage of Medicare beneficiaries do not take their blood pressure medications as directed, according to the CDC?
A minimum of ___________ should elapse before patients who take patiromer for treatment of hyperkalemia ingest other oral medications.
Back to Top